Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
12.99
-0.02 (-0.15%)
At close: Jul 1, 2025, 4:00 PM
13.50
+0.51 (3.93%)
After-hours: Jul 1, 2025, 7:12 PM EDT
ARCT Employees
As of December 31, 2024, Arcturus Therapeutics Holdings had 176 total employees, including 174 full-time and 2 part-time employees. The number of employees decreased by 4 or -2.22% compared to the previous year.
Employees
176
Change (1Y)
-4
Growth (1Y)
-2.22%
Revenue / Employee
$816,364
Profits / Employee
-$387,500
Market Cap
352.30M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ARCT News
- 1 day ago - Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program - Business Wire
- 8 days ago - Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency - Business Wire
- 4 weeks ago - Arcturus Therapeutics to Attend Upcoming Investor Conferences - Business Wire
- 7 weeks ago - Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress - Business Wire
- 2 months ago - Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025 - Business Wire
- 2 months ago - Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 - Business Wire
- 4 months ago - Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript - Seeking Alpha